Statement on HPV DNA test utilization

✍ Scribed by Diane Solomon; Jacalyn L. Papillo; Diane D. Davey

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 96 KB
• Volume: 37
• Category: Article
• ISSN: 8755-1039
• DOI: 10.1002/dc.21097

✦ Synopsis

Testing for carcinogenic or high-risk human papillomavirus (HPV) DNA has proven utility in cervical cancer screening and in many aspects of clinical management for cervical cancer prevention. However, inappropriate testing increases costs without benefit and potentially results in over-treatment of women. This Statement was developed by the Cytopathology Education and Technology Consortium and has been endorsed by additional professional medical societies as listed below. It is intended as a concise, convenient summary of clinical indications for HPV DNA test utilization based on the American Cancer Society 2002 screening recommendations 1 and interim guidance, 2 and the 2006 American Society for Colposcopy and Cervical Pathology (ASCCP) consensus management guidelines. 3 Circumstances in which HPV DNA testing is considered appropriate, and when such testing is generally not appropriate, are outlined below. This statement and table are intended to serve as educational tools and reference to improve management of women and reduce inappropriate use of HPV tests (Table ).